K.M. Kazemier

1.1k total citations
17 papers, 840 citations indexed

About

K.M. Kazemier is a scholar working on Public Health, Environmental and Occupational Health, Pediatrics, Perinatology and Child Health and Molecular Biology. According to data from OpenAlex, K.M. Kazemier has authored 17 papers receiving a total of 840 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Public Health, Environmental and Occupational Health, 7 papers in Pediatrics, Perinatology and Child Health and 6 papers in Molecular Biology. Recurrent topics in K.M. Kazemier's work include Acute Lymphoblastic Leukemia research (11 papers), Drug Transport and Resistance Mechanisms (5 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers). K.M. Kazemier is often cited by papers focused on Acute Lymphoblastic Leukemia research (11 papers), Drug Transport and Resistance Mechanisms (5 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers). K.M. Kazemier collaborates with scholars based in Netherlands, Germany and United States. K.M. Kazemier's co-authors include A. Veerman, Rob Pieters, Monique L. den Boer, Gertjan J.L. Kaspers, J.C. Grutters, Elisabetta Fortunati, Leo Koenderman, G. Henze, G. Janka‐Schaub and C. Michel Zwaan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

K.M. Kazemier

17 papers receiving 831 citations

Peers

Countries citing papers authored by K.M. Kazemier

Since Specialization

Citations

This map shows the geographic impact of K.M. Kazemier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.M. Kazemier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.M. Kazemier more than expected).

Fields of papers citing papers by K.M. Kazemier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.M. Kazemier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.M. Kazemier. The network helps show where K.M. Kazemier may publish in the future.

Co-authorship network of co-authors of K.M. Kazemier

This figure shows the co-authorship network connecting the top 25 collaborators of K.M. Kazemier. A scholar is included among the top collaborators of K.M. Kazemier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.M. Kazemier. K.M. Kazemier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	The detrimental effect of quantity of smoking on survival in progressive fibrosing ILD 2022 ·Respiratory Medicine ·(unknown), Joanne J. van der Vis, K.M. Kazemier, Jan C. Grutters, Coline H.M. van Moorsel	7
2	Humoral Immune Status in Relation to Outcomes in Patients with Idiopathic Pulmonary Fibrosis 2021 ·Lung ·Thijs W. Hoffman, Coline H.M. van Moorsel, K.M. Kazemier, Douwe H. Biesma, Jan C. Grutters, Diana A. van Kessel	2
3	Polymorphism in C-C Chemokine Receptor 5 (CCR5) increases susceptibility to Löfgren’s syndrome and alters receptor expression as well as functional response 2021 ·(unknown), Coline H.M. van Moorsel, Marcel Veltkamp, Corina C.G. Benschop, K.M. Kazemier, (unknown), T. Huizinga, Jan C. Grutters, G T Rijkers	2
4	The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97) 2011 ·Haematologica ·Gabriele Escherich, (unknown), U. Göbel, Ulrike Graubner, Arnulf Pekrun, Norbert Jorch, Gertjan J.L. Kaspers, Martin Zimmermann, Udo zur Stadt, K.M. Kazemier, Rob Pieters, Monique L. den Boer, (unknown), Gritta Janka, (unknown)	18
5	MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases 2010 ·Clinical & Experimental Immunology ·N.M. Korthagen, (unknown), Coline H.M. van Moorsel, K.M. Kazemier, Jules M.M. van den Bosch, Jan C. Grutters	34
6	Effect of variation in ITGAE on risk of sarcoidosis, CD103 expression, and chest radiography 2009 ·Clinical Immunology ·Michiel Heron, Jan C. Grutters, Coline H.M. van Moorsel, Henk J.T. Ruven, K.M. Kazemier, A.M.E. Claessen, Jules M.M. van den Bosch	9
7	Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study 2008 ·Leukemia ·Inge M. Appel, K.M. Kazemier, Joachim Boos, Claudia Lanvers, (unknown), A. Veerman, ER van Wering, Monique L. den Boer, Rob Pieters	90
8	Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease 2008 ·Clinical & Experimental Immunology ·Elisabetta Fortunati, K.M. Kazemier, J.C. Grutters, Leo Koenderman, (unknown)	117
9	Patient Stratification Based on Prednisolone-Vincristine-Asparaginase Resistance Profiles in Children With Acute Lymphoblastic Leukemia 2003 ·Journal of Clinical Oncology ·Monique L. den Boer, D. Harms, Rob Pieters, K.M. Kazemier, U. Göbel, Dieter Körholz, Ulrike Graubner, R. Haas, Norbert Jorch, H. Spaar, Gertjan J.L. Kaspers, Willem A. Kamps, A van der Does-van den Berg, Elisabeth R. van Wering, A. Veerman, Gritta Janka‐Schaub	133
10	Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia 1999 ·Leukemia ·Monique L. den Boer, Rob Pieters, K.M. Kazemier, (unknown), G. Henze, A. Veerman	31
11	Myeloid antigen co‐expression in childhood acute lymphoblastic leukaemia: relationship with in vitro drug resistance 1999 ·British Journal of Haematology ·Monique L. den Boer, Petra Kapaun, Rob Pieters, K.M. Kazemier, G. Janka‐Schaub, A. Veerman	19
12	Different expression of glutathione S‐transferase α, μ and π in childhood acute lymphoblastic and myeloid leukaemia 1999 ·British Journal of Haematology ·Monique L. den Boer, Rob Pieters, K.M. Kazemier, G. Janka‐Schaub, G. Henze, Ursula Creutzig, Gertjan J.L. Kaspers, Pamela Kearns, Andrew G. Hall, Andrew D.J. Pearson, A. Veerman	25
13	The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia 1998 ·Leukemia ·Monique L. den Boer, Rob Pieters, K.M. Kazemier, (unknown), G. Henze, A. Veerman	22
14	Relationship Between Major Vault Protein/Lung Resistance Protein, Multidrug Resistance-Associated Protein, P-Glycoprotein Expression, and Drug Resistance in Childhood Leukemia 1998 ·Blood ·Monique L. den Boer, Rob Pieters, K.M. Kazemier, M. M. A. Rottier, C. Michel Zwaan, Gertjan J.L. Kaspers, G. Janka‐Schaub, G. Henze, Ursula Creutzig, Rik J. Scheper, A. Veerman	108
15	Relationship Between Major Vault Protein/Lung Resistance Protein, Multidrug Resistance-Associated Protein, P-Glycoprotein Expression, and Drug Resistance in Childhood Leukemia 1998 ·Blood ·Monique L. den Boer, Rob Pieters, K.M. Kazemier, M. M. A. Rottier, C. Michel Zwaan, Gertjan J.L. Kaspers, G. Janka‐Schaub, G. Henze, Ursula Creutzig, Rik J. Scheper, A. Veerman	74
16	Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia 1997 ·Leukemia ·Monique L. den Boer, C. Michel Zwaan, R. Pieters, K.M. Kazemier, (unknown), M J Flens, RJ Scheper, A. Veerman	41
17	Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay 1994 ·British Journal of Cancer ·Gertjan J.L. Kaspers, A. Veerman, Rob Pieters, GJ Broekema, (unknown), K.M. Kazemier, (unknown), (unknown), (unknown), K. Hählen	108

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact